Blog

Cybin Completes Enrollment in Phase 2 Study of CYB003 in Major Depressive Disorder

Sep 21 • 4 min read

–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase 1/2 data for pivotal studies – – Breakthrough Therapy designation anticipated in late 2023, subject to FDA approval – – Previously announced acquisition of Small Pharma Inc. expected to close in…

Filament Health and Jaguar Health Joint Venture Magdalena Biosciences Completes Import of Coca Leaf From Peru

Sep 21 • 4 min read

The import to Filament’s Metro Vancouver facility was conducted in collaboration with the Peruvian government and facilitated by Filament Health and Jaguar Health Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or “Filament Health”), a clinical-stage natural psychedelic drug development company, today announced that Magdalena Biosciences (“Magdalena”), a joint venture formed by Filament and Jaguar Health, Inc. (Nasdaq: JAGX) (“Jaguar…

Lucy Scientific Discovery: Navigating Growth and Diversification in the Psychedelic and Wellness Sectors

Sep 20 • 6 min read

This has been a busy quarter for the psychedelic industry, particularly Lucy Scientific Discovery Inc. The company has announced three acquisitions in the past three months. These acquisitions create an interesting and unexpected pathway for the company. The NASDAQ-listed Lucy Scientific Discovery has greatly expanded its reach within the psychedelic, wellness, and cannabis industries this…

Interview with Red Light Holland CEO, Todd Shapiro

Sep 20 • 1 min read

Psychedelic Invest’s Charley Rose sat down with the CEO of Red Light Holland, Todd Shapiro. During the interview, Charley does a deep dive into the company and its current positioning in the market. Red Light Holland is an expansive collection of mushroom brands. Todd Shapiro offers a fun and unique perspective on the global psychedelic…

Silo Pharma Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug (IND) Application with FDA

Sep 20 • 3 min read

Silo Pharma, Inc. (Nasdaq: SILO) (“the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548